Genmab
GMAB
227 hedge funds and large institutions have $1.72B invested in Genmab in 2020 Q4 according to their latest regulatory filings, with 53 funds opening new positions, 85 increasing their positions, 63 reducing their positions, and 21 closing their positions.
152% more first-time investments, than exits
New positions opened: 53 | Existing positions closed: 21
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
35% more repeat investments, than reductions
Existing positions increased: 85 | Existing positions reduced: 63
15% more capital invested
Capital invested by funds: $1.5B → $1.72B (+$220M)
15% more funds holding
Funds holding: 198 → 227 (+29)
1.84% more ownership
Funds ownership: 62.58% → 64.42% (+1.8%)
4% more call options, than puts
Call options by funds: $3.57M | Put options by funds: $3.44M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$20.1M |
| 2 |
Capital International Investors
Los Angeles,
California
|
+$13.7M |
| 3 |
First Trust Advisors
Wheaton,
Illinois
|
+$13.2M |
| 4 |
Jennison Associates
New York
|
+$13.1M |
| 5 |
Invesco
Atlanta,
Georgia
|
+$10.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$18.3M |
| 2 |
Renaissance Technologies
New York
|
-$13.2M |
| 3 |
MWNA
Marshall Wace North America
New York
|
-$12.9M |
| 4 |
Morgan Stanley
New York
|
-$12.1M |
| 5 |
Artisan Partners
Milwaukee,
Wisconsin
|
-$11.9M |
GMAB Hedge Fund Activity: Q4 2020 in Review
227 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Genmab (GMAB) for Q4 2020, worth a combined $1.72B — up 15% from $1.5B a quarter earlier.
Buyers outnumbered sellers: 53 funds opened new GMAB positions and 21 closed out — a net gain of 32 holders — while 85 added to existing stakes and 63 trimmed.
The largest buyer was Goldman Sachs, adding an estimated $20.1M. The largest seller was Adage Capital Partners, exiting entirely with an estimated $18.3M sold.
- 227 institutional investors held Genmab (GMAB) as of Q4 2020, up from 198 in Q3 2020.
- Funds reported $1.72B of Genmab stock for Q4 2020, up 15% quarter-over-quarter.
- 53 funds opened new Genmab positions in Q4 2020 and 21 closed out, a net change of +32 holders.
- The largest Genmab buyer in Q4 2020 was Goldman Sachs, an estimated $20.1M added.
- The largest Genmab seller in Q4 2020 was Adage Capital Partners, an estimated $18.3M sold.
Based on aggregated 13F filings for Q4 2020.